Evaxion Biotech A/S (EVAX) |
|
0.859 -0.001 (-0.12%)
|
10-02 16:00 |
|
Open: |
0.88 |
Pre. Close: |
0.86 |
|
High:
|
0.88 |
Low:
|
0.8151 |
|
Volume:
|
63,719 |
Market Cap:
|
24(M) |
|
|
|
Technical analysis |
as of: 2023-10-02 4:49:56 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 1.07  One year: 1.25 |
| Support: |
Support1: 0.64 Support2: 0.46 |
| Resistance: |
Resistance1: 0.92 Resistance2: 1.07 |
| Pivot: |
0.74  |
| Moving Average: |
MA(5): 0.83 MA(20): 0.74
MA(100): 1.16 MA(250): 1.54 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 83.8 %D(3): 82.3 |
| RSI: |
RSI(14): 53.5 |
| 52-week: |
High: 3.09 Low: 0.46 |
| Average Vol(K): |
3-Month: 122 (K) 10-Days: 397 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EVAX ] has closed below upper band by 21.1%. Bollinger Bands are 24.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.88 - 0.88 |
0.88 - 0.89 |
|
Low:
|
0.81 - 0.81 |
0.81 - 0.81 |
|
Close:
|
0.85 - 0.86 |
0.86 - 0.86 |
|
Company Description |
|
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark. |
Headline News |
Thu, 21 Sep 2023
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab - Nasdaq
Wed, 20 Sep 2023
Other news to note for Sept. 20, 2023 - BioWorld Online
Wed, 20 Sep 2023
Evaxion Partners With Pharmaceutical Company Afrigen Biologics ... - GlobeNewswire
Mon, 18 Sep 2023
Evaxion expands preclinical bacterial vaccine pipeline in ... - BioSpace
Mon, 11 Sep 2023
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI ... - BioSpace
Tue, 29 Aug 2023
Evaxion announces Executive Management Changes to strengthen ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
28 (M) |
| Shares Float |
19 (M) |
|
% Held by Insiders
|
32.7 (%) |
|
% Held by Institutions
|
1.1 (%) |
|
Shares Short
|
175 (K) |
|
Shares Short P.Month
|
332 (K) |
Stock Financials |
|
EPS
|
-1.55 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.09 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-60.8 |
|
Return on Equity (ttm)
|
-216.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.88 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-24 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-0.56 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
9.54 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.01 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
